At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Research genetic analysis (genetic)
- How long the study runs
- Study runs about 94 months (dates as stated)
- About the drug or intervention
- Research genetic analysis — genetic: Genetic analysis of DNA extracted from saliva.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 10,000
- Started
- 2019-11-09
- Last checked
- 2026-03
Plain English Summary
What is this study?
- • Testing a new treatment for cardiomyopathies
- • Clinical study - 10,000 participants
- • This is an online registry and database of patients with cardiomyopathy and myocarditis, coupled with an observational study of cardiomyopathies
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with cardiomyopathies
Where?
- • London - Imperial College London
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This is an online registry and database of patients with cardiomyopathy and myocarditis, coupled with an observational study of cardiomyopathies.
More detail
This study utilises The Heart Hive, an international, online registry of patients with self-reported clinically diagnosed cardiomyopathy or myocarditis, and people with a family history of cardiomyopathy, enrolled on an on-going basis. Registry participants are invited to enter self-reported demographics and health data relevant to their cardiac diagnosis into The Heart Hive online database. Registry participants with self-reported clinically diagnosed cardiomyopathy will be recruited to an observational, prospective study entailing collection of patient-reported baseline demographic data and clinical risk factors, genotyping, and annual collection of follow up data from patients, national registries (NHS England) and medical records. In the pilot phase 100 DCM and 100 HCM patients will be recruited to a validation study. Consent will be sought to access medical information from health care providers in order to compare against and confirm self-reported health information. DNA will be obtained from saliva samples and tested in-house using a panel of clinically validated known Mendelian DCM and HCM genes as a second validation of the accuracy of self-reported diagnosis and to confirm equivalent genetic architecture of DCM and HCM in direct-to-patient recruited cohorts compared to traditional centre of excellence clinic-based recruitments. Following validation of the approach and once funding is in place for genomic studies, larger numbers of cardiomyopathy patients will be recruited to this study from the registry of research willing participants.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Adult (age 18 and over),
- ✓Males and Females,
- ✓Capacity to provide agreement to take part,
- ✓Patients with a confirmed diagnosis of cardiomyopathy or myocarditis,
- ✓People with a family history of cardiomyopathy confirmed in a first or second degree relative.
Who cannot take part
- ✗Patients who lack capacity to consent for themselves,
- ✗Vulnerable groups (e.g. those under 18, prisoners, those in a dependent relationship, the mentally ill).
- ✗Patients with a confirmed history of coronary artery disease:
- ✗who have been informed by their treating physician that their cardiomyopathy is secondary to their coronary artery...
- ✗who have undergone previous percutaneous coronary intervention or coronary bypass surgery
See the full criteria
Where Is This Study? (1 UK site)
Imperial College London
London, United Kingdom
How to Get in Touch
Rachel Buchan, MD PhD
Sponsor contactCONTACT
